LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.12 -1.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.11

Max

1.15

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-31M 72M
Eelmine avamishind	2.87
Eelmine sulgemishind	1.12

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. veebr 2026, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. veebr 2026, 23:35 UTC

Tulu

Suurimad hinnamuutused turgudel

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. veebr 2026, 23:28 UTC

Tulu

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. veebr 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. veebr 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. veebr 2026, 23:33 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. veebr 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. veebr 2026, 22:55 UTC

Tulu

Kuumad aktsiad

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. veebr 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. veebr 2026, 22:23 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. veebr 2026, 22:00 UTC

Tulu

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. veebr 2026, 21:57 UTC

Tulu

XP 4Q Rev BRL4.95B >XP

12. veebr 2026, 21:52 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. veebr 2026, 21:47 UTC

Tulu

Morningstar 4Q Rev $641M >MORN

12. veebr 2026, 21:39 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:38 UTC

Tulu

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.